The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.75
Bid: 15.50
Ask: 16.00
Change: -0.50 (-3.08%)
Spread: 0.50 (3.226%)
Open: 16.25
High: 16.25
Low: 15.70
Prev. Close: 16.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Appreciate gets court date; Corcel completes sale

Wed, 25th Jan 2023 20:03

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Appreciate Group PLC - Merseyside, England-based multi-retailer redemption product provider to corporate and consumer markets - Says that the court hearing to sanction the acquisition by PayPoint PLC will be held in the Royal Courts of Justice on February 23. In November, the Hertfordshire, England-based payment services provider PayPoint said it is buying Appreciate in a deal that values the company at around GBP83 million. PayPoint will pay 33 pence in cash and 0.019 of a new PayPoint share for each Appreciate share. PayPoint expects the takeover scheme to become effective in the first half of 2023.

----------

Corcel PLC - London-based mining and mineral resource development company - Completes the sale of a 100% stake in the Burwell Energy Storage project outside of Cambridge to Burwell AL Ltd for cash proceeds of GBP200,000, plus reimbursement of Corcel's grid deposit of GBP50,000. The outstanding balance of its corporate debt is GBP672,941, it says. "The sale of the Burwell energy storage project amidst ongoing timing uncertainties and potentially substantial additional upgrade costs at the local substation, completes the closure of the Flexible Grid Solutions business, which has been unwound at a small profit," CEO Scott Kaintz comments.

----------

Totally PLC - Derby, England-based provider of healthcare, corporate fitness and wellbeing services - Notes that its subsidiary Greenbrook Healthcare Ltd terminated its contracts for the provision of urgent treatment centres Central Middlesex Hospital, Ealing Hospital and Hillingdon Hospital. The contracts were due to expire on January 31, it adds. Says that Greenbrook will continue to provide services at the urgent treatment centres until there is an orderly handover to a temporary provider.

----------

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Picks up on an increased focus on the importance of infection prevention by the Center for Disease Control, Food & Drug Administration, and the medical community in general. Says that it is currently developing the XF-73 Nasal gel for the prevention of post-surgical infections. "The Centre for Disease Control's announcement clearly recognizes the need for new and effective decolonization agents and their importance for public health. They have made a clear call to simplify the pathway to regulatory approval and suggested the need for establishing new surrogate endpoints. Destiny Pharma views this as a very encouraging shift in the agency's thinking that could be very supportive to our clinical development of XF-73 Nasal," Chief Medical Officer Yuri Martina comments.

----------

AQRU PLC - London-based decentralised finance incubator - Notes that its subsidiary Accru Finance Ltd launched a liquidity pool to allow investors to generate yield from tax credit receivables originating from US Internal Revenue Service programmes. "We look forward to seeing retail and institutional investors worldwide take advantage of this opportunity to generate significant returns in the crypto and decentralised finance sectors," Chief Executive Philip Blows comments.

----------

East Star Resources PLC - gold and copper exploration company focused on Kazakhstan - Identifies a substantial copper-lead-zinc deposit at Rudny Altai VMS belt in Kazakhstan. Says that the deposit is within the greater Verkhuba Ore District. Reports historical flotation recovery rates of 94% to 96% copper and 60% to 90% zinc into concentrate. "Rudny Altai is a significant copper-producing region with excess processing capacity from both Glencore and KAZ Minerals. The identification of the Verkhuba Deposit is yet another validation our exploration thesis and we are excited to commence resource delineation drilling with additional updates to be delivered as digitisation of historic drilling continues and the 2023 exploration programme commences," CEO Alex Walker comments.

----------

Wentworth Resources PLC - Tanzania-focused natural gas production company - Notes that the operator of the Mnazi Bay asset got a notification from Tanzania Petroleum Development Corp in relation to the settlement of gas purchase invoices, which states that TPDC has requested that all future gas purchase invoices be settled in Tanzanian shillings by applying the exchange rate available on the date of payment. Expects this matter to be the subject of further discussion between the operator and TPDC.

----------

Gresham House Renewable Energy VCT 1 - investment firm - Cancels its interim dividend of 2 pence announced on December 21. Explains that a valuation adjustment which had previously been made to certain investments held by VCT 1 was reclassified as a realised loss. Believes that the distributable reserves of VCT 1 are reduced to a level at which the proposed interim dividend should not be paid.

----------

Landore Resources Ltd - Mining exploration and development company in Canada - Finds 822 parts per million nickel, 1087ppm copper, and 81 parts per billion platinum on the Felix-Lamaune prospects at its Junior Lake Property in Ontario, Canada. "The exploration campaign on the Felix-Lamaune area has clearly confirmed that, in addition to the advanced 1.5 million ounce BAM Gold deposit, the Junior Lake property hosts significant volumes of highly valuable battery metals, including palladium enriched sulphide Nickel with associated Cobalt and Copper, the presence of which has now been established through drilling for 11 kilometres from the Carrot Top Zone in the west to the B4-7, Alpha zone and VW Nickel-Copper-Cobalt-PGEs compliant deposits in the east, with the remaining 20 kilometres of the highly prospective greenstone-shear zone, transecting Landore's Junior Lake property, yet to be explored," CEO Bill Humphries says.

----------

Predator Oil & Gas Holdings PLC - operator of Guercif petroleum agreement onshore Morocco and developer of onshore fields in Trinidad - Suspends the MOU-2 well with an option to re-enter after reaching a depth of 1,260 metres measured depth. Says that the MOU-1 testing programme is being progressed and revised to gather as much information as possible on the connectivity of potential gas sands over a wide area. "MOU-2 has been an extremely challenging well to drill due to the presence of a particular geological formation not previously encountered. The prudent and safer option was to suspend the well and leave it in a state to re-enter once a better understanding of the mud programme required to drill this particularly complex interval efficiently and cost-effectively. Whilst this is not the result we wanted the pre-drill objectives and potential resources remain unchanged. The Star Valley rig will remain in place over the wellhead," Executive Chair Paul Griffiths comments.

----------

By Abby Amoakuh, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
22 Dec 2022 11:25

Destiny Pharma on track for commercial agreement for NTCD-M3 drug

(Alliance News) - Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.

Read more
7 Dec 2022 17:35

Destiny Pharma eyes potential billion dollar returns from Nasal asset

(Alliance News) - Destiny Pharma PLC on Wednesday said it has finalised development plans for phase three testing of its late-stage clinical asset, XF-73 Nasal, which aims to prevent post-surgical staphylococcal infections.

Read more
7 Dec 2022 16:27

Destiny Pharma finalises plans for next study of its lead asset

(Sharecast News) - Biotechnology company Destiny Pharma has finalised plans for phase-three studies of its late-stage clinical asset 'XF-73 Nasal', it announced on Wednesday.

Read more
15 Nov 2022 16:16

Destiny Pharma starts new drug study for its skin infection treatment

(Alliance News) - Destiny Pharma PLC on Tuesday said it had started a safety study to enable its XF-73 treatment to be labelled as an Investigational New Drug.

Read more
15 Nov 2022 12:53

Destiny Pharma starts new safety study of dermal formulation

(Sharecast News) - Biotechnology developer Destiny Pharma announced the start of an investigational new drug (IND)-enabling safety study with its novel 'XF-73 Dermal' formulation.

Read more
8 Sep 2022 15:17

Destiny Pharma loss widens, pins hope on late stage clinical assets

(Alliance News) - Destiny Pharma PLC on Thursday reported a widened interim loss, as it progresses two key clinical assets.

Read more
7 Sep 2022 17:21

Destiny Pharma gets positive EMA feedback for gut bacteria treatment

(Alliance News) - Destiny Pharma PLC on Wednesday announced that it had received positive feedback from the European Medicine Agency on its NTCD-M3 phase 3 development plans.

Read more
7 Sep 2022 08:06

Destiny Pharma receives 'positive feedback' from EMA on NTCD-M3

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma has received "positive feedback" from the European Medicine Agency regarding the proposed Phase III development programme of its new antibiotic treatment.

Read more
1 Sep 2022 15:59

UK earnings, trading statements calendar - next 7 days

Friday 2 September 
Ashmore Group PLCFull Year Results
Monday 5 September 
Belvoir Group PLCHalf Year Results
Dechra Pharmaceuticals PLCFull Year Results
Tuesday 6 September 
Accrol Group Holdings PLCFull Year Results
Alumasc Group PLCFull Year Results
Ashtead Group PLCQ1 Results
Capricorn Energy PLCHalf Year Results
Gamma Communications PLCHalf Year Results
Headlam Group PLCHalf Year Results
Inspired PLCHalf Year Results
IQE PLCHalf Year Results
Lords Group Trading PLCHalf Year Results
Luceco PLCHalf Year Results
Michelmersh Brick Holdings PLCHalf Year Results
Midwich Group PLCHalf Year Results
NCC Group PLCFull Year Results
PCI-PAL PLCFull Year Results
Pebble Group PLCHalf Year Results
Quixant PLCHalf Year Results
STV Group PLCHalf Year Results
WAG Payment Solutions PLCHalf Year Results
WANdisco PLCHalf Year Results
Wednesday 7 September 
Bakkavor Group PLCHalf Year Results
Barratt Developments PLCFull Year Results
Equals Group PLCHalf Year Results
M Winkworth PLCHalf Year Results
Malin Corp PLCHalf Year Results
Petropavlovsk PLCHalf Year Results
Somero Enterprises IncHalf Year Results
Tissue Regenix Group PLCHalf Year Results
WH Smith PLCTrading Statement
Thursday 8 September 
Arecor Therapeutics PLCHalf Year Results
Cairn Homes PLCHalf Year Results
Curtis Banks Group PLCHalf Year Results
Darktrace PLCFull Year Results
Destiny Pharma PLCHalf Year Results
Duke Royalty LtdFull Year Results
Emis Group PLCHalf Year Results
Energean PLCHalf Year Results
Funding Circle Holdings PLCHalf Year Results
Genus PLCFull Year Results
International Public Partnerships LtdHalf Year Results
Melrose Industries PLCHalf Year Results
Mpac Group PLCHalf Year Results
Oakley Capital Investments LtdHalf Year Results
Open Orphan PLCHalf Year Results
Restaurant Group PLCHalf Year Results
Safestore Holdings PLCQ3 Results
Severfield PLCFull Year Results
Shield Therapeutics PLCHalf Year Results
SourceBio International PLCHalf Year Results
Spire Healthcare Group PLCHalf Year Results
Sylvania Platinum LtdFull Year Results
Vistry Group PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
26 Jul 2022 22:16

TRADING UPDATES: De La Rue cancels contract; Apollon buys in Jamaica

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
19 Jul 2022 20:01

TRADING UPDATES: Capital backs outlook; Northcoders trades well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
12 Jul 2022 15:39

Destiny Pharma awarded Cystic Fibrosis Foundation project

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation, it announced on Tuesday.

Read more
12 Jul 2022 12:07

IN BRIEF: Destiny Pharma receives undisclosed grant for MRSA study

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Receives undisclosed grant from Maryland-based non profit Cystic Fibrosis Foundation for a study on its drug candidate XF-73 on disease-causing bacteria MRSA.

Read more
7 Jul 2022 20:38

IN BRIEF: Destiny Pharma XF-73 shown to enhance activity of two drugs

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - New data on its XF-73 drug show that it can boost the effectiveness of current standard of care antibiotics when used in combinational therapy. The new in-vitro data stemmed from experiments by studies at the School of Dentistry, Cardiff University, for the potential for XF-based drugs to enhance the effectiveness of key antibacterial treatments. When combined with polymyxin B, a last resort antibacterial drug used to treat life-threatening lung bacterial infections, XF-73 enhanced polymyxin B potency against Pseudomonas aeruginosa, a top priority WHO bacterial pathogen, by 4-fold, the research found.

Read more
5 Jul 2022 11:43

IN BRIEF: Destiny Pharma begins research on XF-73 for oral mucositis

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Starts new research programme in the US on oral mucositis, an inflammation of the mouth that is a common side effect of chemotherapy and radiotherapy. Firm tests its experimental drug candidate XF-73 as potential preventive medicine to ease suffering from oral mucositis. Explains that XF-73 has shown unique antimicrobial properties in phase 2 clinical trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.